Replies to post #318122 on Amarin Corp Plc (AMRN)

[Gbert]

What niche would they fill?

No CV outcome data.

Combined EPA/DHA....not proven to be superior.

For specifically lowering TGs - cheaper options available and those patients would like be on a statin as well.

[Biobillionair]

Are we worried about the enhanceIT trail?

STRENGTH trial failure should secure FDA’s position that a CVOT is needed for a wide cardiovascular treatment label.
BB

[couldbebetter]

Gusman, Here is my conspiracy theory (not totally serious.) Matinas
has some sort of a JV/relationship with Roche (using something Matinas
has as a drug delivery system.) What if Roche is wanting Matinas to do
(and promote) this "head to head" study as a way to slam Vascepa and
to help keep a lid on the share price of AMRN? Why would Roche want
to do that? Maybe they would want to acquire AMRN at a low price.

Dr. Nissen has disparaged Vascepa and the Reduce-It Trial results as
well despite the science to the contrary. My guess is that Nissen is
bought and paid for many times over by BP and his efforts to destroy
AMRN's short term prospects may be related to some BP that may wish
to pick up AMRN for a far lower price than they might have been willing
to pay years ago. If BP manages to acquire AMRN for say $24 a share
because of their fu#kery instead of a $34 price that may have been
believed to be reasonable at one time, that would be a savings of
$4.17 billion! (Not exactly chicken feed, but enough in savings to
keep a Dr. Nissen in ones back pocket. (Just a conspiracy theory.)

[funnygi2]

It’s not EPA and DHA. It’s a mixture of EPA and DPA. Plus they have other medications in development unrelated to lipid reduction.